|
UBE2V1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.14679999996259E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.54490000001417E-06 |
| Normal-vs-Stage2 |
9.330400E-01 |
| Normal-vs-Stage3 |
1.00459999996527E-06 |
| Normal-vs-Stage4 |
2.71389999995097E-06 |
| Stage1-vs-Stage2 |
3.240200E-03 |
| Stage1-vs-Stage3 |
2.483600E-01 |
| Stage1-vs-Stage4 |
1.189760E-01 |
| Stage2-vs-Stage3 |
4.989300E-04 |
| Stage2-vs-Stage4 |
4.049400E-04 |
| Stage3-vs-Stage4 |
5.105600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.67639999951675E-08 |
| Normal-vs-AfricanAmerican |
3.332400E-01 |
| Normal-vs-Asian |
5.033500E-04 |
| Caucasian-vs-AfricanAmerican |
9.770400E-02 |
| Caucasian-vs-Asian |
4.369600E-01 |
| AfricanAmerican-vs-Asian |
3.023600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.816900E-03 |
| Normal-vs-Female |
2.57970000028251E-07 |
| Male-vs-Female |
9.791700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.241380E-04 |
| Normal-vs-Age(41-60Yrs) |
1.58110000003653E-06 |
| Normal-vs-Age(61-80Yrs) |
1.164670E-03 |
| Normal-vs-Age(81-100Yrs) |
2.254100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.930200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.684000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.852400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.476200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.969400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.832800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.400500E-02 |
| Classical-VS-Follicular |
1.417560E-02 |
| Classical-VS-Other |
4.343400E-01 |
| Classical-VS-Normal |
4.69770000000036E-06 |
| Tall-VS-Follicular |
8.2277000000075E-05 |
| Tall-VS-Other |
6.475200E-01 |
| Tall-VS-Normal |
4.64670000255296E-08 |
| Follicular-VS-Other |
1.641390E-01 |
| Follicular-VS-Normal |
2.763600E-01 |
| Other-VS-Normal |
1.240020E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.816800E-04 |
| Normal-vs-N1 |
3.809500004337E-08 |
| N0-vs-N1 |
1.219920E-03 |
|
|
